Pseudomonas aeruginosa can cause sight-threatening corneal infections in humans, particularly those who wear contact lenses. We have previously shown that a live-attenuated P. aeruginosa vaccine given intranasally protected mice against acute lethal pneumonia in a lipopolysaccharide (LPS) serogroup-specific manner. In the current study, we evaluated the protective and therapeutic efficacies, as well as the target antigens, of this vaccine in a murine corneal infection model. C3H/HeN mice were nasally immunized with the vaccine (an aroA deletion mutant of strain PAO1, designated PAO1⌬aroA) or with Escherichia coli as a control and were challenged 3 weeks later by inoculating the scratch-injured cornea with P. aeruginosa. For passive prophylaxis and therapy, we utilized a serum raised in rabbits nasally immunized with PAO1⌬aroA or E. coli. Outcome measures included corneal pathology scores and, in some experiments, reductions in total and internalized bacterial CFU. We found that both active and passive immunization reduced corneal pathology scores after challenge with a variety of P. aeruginosa strains, including several serogroup-heterologous strains. Even when given therapeutically starting as late as 24 h after infection, the rabbit antiserum to PAO1⌬aroA was effective at reducing corneal pathology scores. Immunotherapy of established infections also reduced the numbers of total and internalized corneal P. aeruginosa bacteria. Experiments using absorbed sera showed that the protective antibodies are specific to outer membrane proteins. Thus, live-attenuated P. aeruginosa vaccines delivered nasally protect against corneal infections in mice and potentially can be used to prepare passive therapy reagents for the treatment of established P. aeruginosa corneal infections caused by diverse LPS serogroups.
Pseudomonas aeruginosa is the pathogen most frequently isolated in cases of contact lens-associated bacterial keratitis (1, 10, 38, 41) , a rapidly progressive infection that can lead to permanent scarring of the cornea and loss of vision. Even when antibiotic treatment eradicates the offending pathogen, corneal damage from inflammation can still occur (24) . Fluoroquinolones, a class of antibiotics frequently used for treatment of corneal infections in humans, are likely to become ineffective in the coming years judging from data on changing susceptibility patterns of P. aeruginosa corneal isolates (1, 44) . These issues underscore the need for new vaccines or immunotherapies that might prevent or hasten resolution of this sightthreatening infection.
The development of vaccines for P. aeruginosa infections has been hindered by the complexity of the organism's pathogenesis. Elaboration of a wide array of virulence factors and the propensity to infect many different tissues have made it difficult to determine which host immune effectors and which microbial factors need to be targeted for effective immunity (34) . Antibodies directed to the serogroup-determining O antigen on the lipopolysaccharide (LPS) are highly protective in a number of different infection models, including keratitis (29) , but production of an O antigen-based vaccine has been hindered by the extensive antigenic and chemical variation in these antigens combined with poor immunogenicity when multivalent vaccines have been formulated (5, 6, 26, 27) .
We previously reported that nasal immunization of mice and rabbits with an unmarked aroA deletion mutant of the P. aeruginosa serogroup O2/O5 strain PAO1, designated PAO1⌬aroA, was safe and highly immunogenic and could protect mice against acute fatal pneumonia, although the protection did not extend beyond the O2/O5 serogroup strains (31, 33) . In rats, nasal immunization has been reported to be the most efficacious route for protection against corneal infection (42) . In the current study, we evaluated the protective efficacies against murine corneal infection of active and passive immunization with PAO1⌬aroA and of therapy with a rabbit antiserum raised against PAO1⌬aroA. In striking contrast to the serogroup-specific protection seen in acute pneumonia, the PAO1⌬aroA vaccine was effective against corneal infections caused by diverse serogroups of P. aeruginosa. Additionally, the antiserum raised against PAO1⌬aroA was effective therapeutically even when started as late as 24 h after infection. Experiments using antisera absorbed with whole bacteria and outer membrane protein (OMP) preparations indicated that OMP antigens are the targets for the protective antibody in this setting.
three intranasal (i.n.) applications of P. aeruginosa PAO1⌬aroA or Escherichia coli HB101 at 1-week intervals, as previously described (31) . The aroA gene encodes the shikimate-pathway enzyme 5-enolpyruvylshikimate 3-phosphate synthase, which is essential for biosynthesis of aromatic amino acids. Mice were anesthetized with ketamine and xylazine prior to i.n. immunization. The immunizing doses, all in 20-l volumes, increased each week and were 10 8 CFU per mouse the first week, 5 ϫ 10 8 CFU the second week, and 10 9 CFU the third week. All animal experiments conformed to local and federal guidelines for the use of animals in research and adhered to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.
Preparation of antisera for passive immunotherapy. New Zealand White rabbits (Millbrook Breeding Labs, Amherst, MA) were nasally immunized with PAO1⌬aroA or E. coli HB101 by initially using the same doses and schedule as for the mice. The immunizing doses for rabbits were given in volumes of 100 l (50 l per nostril). Starting 4 to 7 weeks after the third immunization, rabbits were given repeated i.n. doses of 10 9 CFU every 2 to 4 weeks. Rabbits were anesthetized with a mixture of atropine, ketamine, and xylazine injected subcutaneously prior to each immunization. Sera for protection studies were obtained after a minimum of four boosting doses.
Antibodies in immune sera were absorbed by incubation with lyophilized P. aeruginosa strains (2 mg/ml) for 3 h at 4°C with gentle mixing by tumbling. Strains used for absorption included PAO1 (serogroup O2/O5), the parental strain of PAO1⌬aroA; 6294 (serogroup O6); 6354 (serogroup O8); AK44, an LPS-defective strain with no O antigen but a complete outer core; and the PAO1 galU mutant, an LPS-defective strain with no O antigen and a truncated outer core (see Table 1 for references). For the PAO1 galU mutant, three successive absorptions were done, each involving overnight incubation at 4°C with 5 mg of dried bacteria per ml serum. The PAO1⌬aroA antiserum was also absorbed with purified O antigen (also called high-molecular-weight O polysaccharide) from P. aeruginosa strain Fisher IT-7 by overnight incubation at 4°C in 100 g/ml of the polysaccharide, which was prepared as previously reported (12) . Following incubation, immune complexes were removed by ultracentrifugation (100,000 ϫ g for 3 h). The absorption steps were repeated once. Titers of immunoglobulin G (IgG) to PAO1 O antigen in absorbed and unabsorbed sera were determined by enzyme-linked immunosorbent assay as described elsewhere (31) . The titer to PAO1 O antigen in the absorbed PAO1⌬aroA antiserum was 32-fold lower than that in the unabsorbed PAO1⌬aroA antiserum and was identical to that in the E. coli HB101 antiserum (data not shown).
For some experiments, PAO1 was heat treated (99°C for 60 min) or protease treated (bacterial protease type XIV, EC 3.4.24.31 [Sigma, St. Louis, MO]; 0.1 mg/ml; 37°C for 2 h), washed with water, lyophilized, and then used for absorption of sera. Following the absorption steps, contaminating LPS was removed from sera by using polymyxin B-agarose (Sigma, St. Louis, MO) according to the manufacturer's instructions, and the detoxified sera were dialyzed and then concentrated back to the original volume.
Corneal infection experiments.
For passive immunization studies, absorbed or unabsorbed sera (0.2 ml) were injected intraperitoneally (i.p.) 18 h prior to corneal challenge and again 1 to 2 h after corneal challenge. For therapeutic efficacy experiments, sera (0.2 ml per dose) were injected i.p. at the time points indicated, starting at least 4 h after infection. Corneal infection was initiated on scratch-injured eyes of anesthetized mice as previously described (28, 47) . Briefly, mice were anesthetized with ketamine and xylazine, and then eyes (one per mouse) were scratched and inoculated with the bacterial inoculum suspended in 5 l of phosphate-buffered saline. Following infection, eyes were assigned a pathology score every 24 h according to the following scheme (3): 0, eye macroscopically identical to the uninfected contralateral control eye; 1, faint opacity partially covering the pupil; 2, dense opacity covering the pupil; 3, dense opacity covering the entire anterior segment; 4, perforation of the cornea, phthisis bulbi (shrinkage of the globe after inflammatory disease), or both. Generally, maximal pathology scores were observed 72 h after infection, so data for this time point are shown in all figures depicting corneal pathology scores except those involving therapy with serum given at 24, 48, and 72 h after infection, where pathology scores at 96 h after infection are listed.
For CFU determinations, mice were euthanized by carbon dioxide overdose 48 h after infection; then eyes were washed and either homogenized in tryptic soy broth containing Triton X-100 (0.5%) to enumerate total bacteria (adherent and internalized) or incubated with gentamicin (0.3 mg/ml) to kill extracellular bacteria, washed to remove the gentamicin, and homogenized in Triton X-100 to release intracellular bacteria for enumeration by serial dilution and plating, all as previously described (8, 46, 47) . Control aliquots of cells were lysed in the presence of gentamicin and the lysates plated on tryptic soy agar to verify that intracellular bacteria were still susceptible to gentamicin at the concentration used.
Preparation of OMPs for serum absorption. A crude preparation of OMPs was isolated using published methods (39) . Briefly, P. aeruginosa PAO1 or its galU mutant was grown to stationary phase at 37°C in chemically defined medium and harvested by centrifugation. The pellet was resuspended in water and broken by sonication. Unbroken cells were removed by centrifugation at 5,000 ϫ g for 10 min. N-Laurylsarcosine, sodium salt (Sigma, St. Louis, MO), was added to the supernatant to a concentration of 2% and then incubated at 20°C for 30 min. The resultant suspension was centrifuged at 38,000 ϫ g for 1 h. The membrane pellet was washed twice with water and then lyophilized. The protein content was estimated using the Bradford reagent. For absorption studies, 10 g of dried OMP was added per ml of serum and allowed to absorb overnight at 4°C.
Statistical analyses. All differences were evaluated with nonparametric statistics. For two-group comparisons the Mann-Whitney U test was used, while for multigroup comparisons the Kruskal-Wallis test with Dunn's correction for pairwise comparisons was used. 
RESULTS
Protection against corneal pathology by active and passive immunization. Active nasal immunization with PAO1⌬aroA elicited a high level of protective efficacy against corneal pathology in P. aeruginosa-infected mice (Fig. 1A) . The mice were fully protected against corneal pathology after challenge with the parental strain PAO1 as well as its cytotoxic variant ExoU ϩ PAO1, which carries the ExoU cytotoxin and its chaperone on a plasmid and is far more virulent than the parental strain in the acute pneumonia model (2) . For PAO1, the minimum 50% infectious dose (ID 50 ), defined by the proportion of mice achieving a pathology score of Ն2 in this model, was previously found to be 2.5 ϫ 10 3 CFU per eye, and the upper limit of the 95% confidence interval (CI) was found to be 2.5 50 ). An uncorrected Kruskal-Wallis test suggested a trend toward protection (P ϭ 0.12) even with this high challenge dose. It should be noted that the expression of challenge doses as multiples of the ID 50 is problematic in the corneal infection model, since we have previously shown that similar numbers of bacteria are associated with the cornea when an inoculum of either 10 8 or 10 5 CFU is used, suggesting that there is a saturation point for infection (8) . To test the duration of protection after active immunization, we challenged mice with strain 6294 (2 ϫ 10 6 CFU) 7 weeks after the final immunization (4 weeks later than the timing of the challenge in the experiments described above) and again found significant (P Ͻ 0.05) protection (data not shown).
To ascertain whether passive immunization could be efficacious in reducing corneal pathology from P. aeruginosa infection, we administered to mice, via i.p. injection, antisera derived from rabbits nasally immunized with PAO1⌬aroA or E. coli HB101 as a control. Passive prophylaxis with a PAO1⌬aroA-specific antiserum was highly effective in preventing corneal infection due to serogroup-homologous strains (Fig. 1B) as well as serogroup-heterologous strains (Fig. 1C ). There was high-level protection against the prototypic members of the O2/O5 serogroup (Fig. 1B) , including strains with variable subtype epitopes (Fisher IT-3, Fisher IT-7, 170006, and 170007) as well as the cytotoxic variant of the parental strain (ExoU ϩ PAO1). Remarkably, there was also significant protection against a number of serogroup-heterologous strains from diverse serogroups (Fig. 1C) , including strains such as 6206 and 6077, which are cytotoxic due to expression of ExoU and, as noted above, are highly virulent in this model.
Immunotherapy of established infection. Because prophylactic administration of immune serum would not likely have clinical utility, we investigated the use of the rabbit antisera as therapy for established corneal infections. We first tested whether a single i.p. dose of antiserum at 4, 8, or 24 h after infection could ameliorate the corneal pathology by 72 h after infection with the parental strain PAO1 given as a challenge dose of 1.4 ϫ 10 7 CFU per eye. The antiserum to PAO1⌬aroA given systemically as a single dose either 4 or 8 h after infection produced significant improvement in corneal pathology scores compared to the control antiserum, while protection was lost if the antiserum was given 24 h after infection ( Fig. 2A) . However, if additional doses were also given at 48 and 72 h after infection (i.e., doses at 24, 48, and 72 h after infection), therapeutic benefit was again seen, with significant reduction in corneal pathology scores not only after infection with the parental strain PAO1 ( Fig. 2A) but also after infection with two LPS-heterologous strains, 6294 and 6077, and nearly significant (P ϭ 0.06) benefit with a fourth heterologous strain, 6354 (Fig.  2B) . In other experiments, a three-dose, early-therapy regimen (Fig. 2C) . This therapeutic regimen (dosing at 4, 8, and 24 h) was studied with a limited number of strains due to its lack of clinical utility in light of doses starting so early after infection.
Antibacterial effect of antiserum to P. aeruginosa PAO1⌬aroA. To assess whether the changes in corneal pathology scores after therapy were correlated with an antibacterial activity and whether the anti-PAO1⌬aroA serum changed the cellular uptake of bacteria during infection, we measured the total and intracellular CFU in infected eyes using gentamicin exclusion assays done 24 h after administration of therapeutic antisera, which was 48 h after infection. In these studies, E. coli or PAO1⌬aroA antiserum was administered i.p. 24 h after infection with PAO1 (2 ϫ 10 7 CFU per eye) or the heterologous strain 6294 (1 ϫ 10 7 CFU per eye). As shown in Fig. 3 , treatment of established corneal infection due to PAO1 with the PAO1⌬aroA antiserum led to roughly 1-log 10 -lower total CFU and 2-log 10 -lower internalized CFU than those for mice treated with the E. coli antiserum, and these differences were statistically significant (P Ͻ 0.01 by Mann-Whitney U tests). At this 48-h time point, corneal pathology scores were significantly lower in the anti-PAO1⌬aroA serum group (data not shown), even though pathology scores 72 h after infection were not significantly different in the experiments for which results are shown in Fig. 2A . Treatment of corneal infection due to the heterologous strain 6294 also produced significant reductions in both total and intracellular CFU compared to the control antiserum, and again the reductions in internalized CFU were of greater magnitude than those in total CFU (Fig. 3) . The high levels of bacterial invasion noted in these experiments are consistent with our previous findings of 10 to 30% invasion 24 h after infection with strain 6294 in C57BL/6 mice (8, 47) . These data suggest that the PAO1⌬aroA antiserum not only has an antibacterial effect but also inhibits internalization of the bacteria by the corneal epithelium, a process we have previously shown to be crucial for the pathogenesis of experimental P. aeruginosa corneal infections (46) .
Determination of protective antigens. Having established that the PAO1⌬aroA antiserum had high levels of both prophylactic and therapeutic efficacy, we next sought to determine the protective antigen(s). Initial experiments evaluated the serogroup specificity of the protection to assess whether antibody to the LPS O antigen was an important immune effector, as we have found in the acute pneumonia model using this vaccine (33) and in the corneal infection model using monoclonal antibodies directed at the O antigen (29) . Absorption of the PAO1⌬aroA antiserum with either the parental strain PAO1, the O antigen-deficient strain AK44, or the vaccine serogroupheterologous strain 6294 (serogroup O6) or 6354 (serogroup O8) significantly diminished the prophylactic efficacy against corneal infection due to PAO1 or 6294 (Fig. 4A) . Absorption of the PAO1⌬aroA antiserum with E. coli HB101 followed by infection with 6294 had no effect on prophylactic efficacy: corneal pathology scores were identical to those achieved by passive administration of the unabsorbed PAO1⌬aroA antiserum (not shown). To confirm further that the protective activity is not removed by absorption with O antigen, we absorbed the PAO1⌬aroA antiserum with purified O antigen from the serogroup O2/O5 strain Fisher IT-7. The O antigen from this strain is known to be highly cross-reactive with that of PAO1. Following absorption, titers of IgG to the purified PAO1 O antigen, as measured by enzyme-linked immunosorbent assay, were the same as those in the E. coli-specific antiserum (data not shown). As shown in Fig. 4C , removal of the O antigenspecific IgG in the PAO1⌬aroA antiserum did not alter the passive protective efficacy against strain 6294. Based on these results, the O antigen was not the protective antigen contained in the PAO1⌬aroA vaccine.
To evaluate whether the protective antigen(s) was a protein or a nonprotein entity, we absorbed the PAO1⌬aroA antiserum with protease-or heat-treated PAO1 and tested the prophylactic efficacies of these manipulated sera against corneal infection with strain 6294 (serogroup O6) or 6487 (serogroup O8). As shown in Fig. 4B , sera absorbed with proteasetreated PAO1 had protective efficacy similar to that of unabsorbed sera, suggesting that the protective antigen(s) is protease sensitive. Heat treatment, however, did not destroy the antigen(s), as protection was lost when the PAO1⌬aroA antiserum was absorbed with heat-treated PAO1 (Fig. 4B) . Taken together, these results suggested that the target antigens could be epitopes on heat-stable proteins or protein-containing molecules such as lipoproteins.
To clarify further the targets of the protective antibody elicited by the PAO1⌬aroA vaccine, we assessed whether antibody to the LPS outer core mediated protection. We hypothesized that such outer-core-specific antibodies might prevent binding of P. aeruginosa to the cystic fibrosis transmembrane conductance regulator on corneal epithelial cells, a critical step in the pathogenesis of P. aeruginosa corneal infection (46) . We therefore absorbed the PAO1⌬aroA antiserum with a galU mutant of PAO1 that expresses an incomplete LPS core and no O antigen (7). This absorbed serum, which should retain antibody to the outer core, was not protective against corneal infection with strain 6294 (Fig. 5A) . Thus, antibody to the outer LPS core did not play a role in protection. We next tested whether the target antigen(s) resided in the OMP fraction. We used OMPs prepared from the galU mutant of PAO1 to avoid any contamination from LPS O antigen, which we initially thought might play a protective role based on our prior studies using monoclonal antibodies to LPS (29) . As shown in Fig. 5B , absorption of the PAO1⌬aroA antiserum with OMPs from the PAO1 galU mutant abrogated the protective efficacy against infection with strain 6294, indicating that the target antigen or antigens reside in the outer membrane fraction. Importantly, as noted above absorption of the PAO1⌬aroA antiserum with E. coli HB101 did not change the protection against strain 6294, suggesting that the target epitopes are specific to P. aeruginosa and are not shared with E. coli.
DISCUSSION
The current studies show that active immunization with a live-attenuated aroA deletion mutant of P. aeruginosa strain PAO1 or administration of a rabbit antiserum raised against this strain can effectively prevent murine corneal infections caused by a number of P. aeruginosa strains of heterologous LPS serogroups and, in the case of the rabbit antiserum, can even treat these infections. In keeping with the lack of serogroup specificity, the results indicate that heat-stable, proteasesensitive antigens within the bacterial outer membrane are the targets of the protective antibody.
What is perhaps most remarkable about these findings is the striking contrast with our results using this vaccine in the setting of acute fatal pneumonia, in which serogroup-heterologous protection was not observed after either active or passive immunization (33) . In fact, in those pneumonia experiments, passive immunization with rabbit IgG derived from the same aeruginosa strain PAO1 or 6294 after administration of a PAO1⌬aroA antiserum previously absorbed with the indicated P. aeruginosa strains. Inocula were 1.1 ϫ 10 7 CFU for both strains. P values for comparison with unabsorbed PAO1⌬aroA antiserum were as follows: ‫,ء‬ P Ͻ 0.04; # , P ϭ 0.10;
, P ϭ 0.13; , P ϭ 0.15. (B) Protective efficacy against corneal infection with P. aeruginosa strain 6294 or 6487 after administration of an antiserum raised against PAO1⌬aroA and previously absorbed with protease-or heat-treated PAO1. Inocula were 1.9 ϫ 10 7 CFU for 6294 and 2.5 ϫ 10 6 CFU for 6487. (C) Protective efficacy against corneal infection with P. aeruginosa strain 6294 after administration of an antiserum raised against PAO1⌬aroA and previously absorbed with purified O antigen from P. aeruginosa strain Fisher IT-7. The inoculum was 1 ϫ 10 6 CFU. For all experiments, antisera were administered i.p. 18 h prior to and 2 h after infection. Each data point represents one eye of one mouse. Corneal pathology scores are described in Materials and Methods. P values were obtained by the Kruskal-Wallis test with Dunn's correction for pairwise comparisons. PAO1⌬aroA antisera used in the current studies protected against challenge only by ExoU ϩ PAO1 and not by PAO1 itself, likely due to the much higher challenge doses needed for lethality with the noncytotoxic strain PAO1. Lack of protection against PAO1-induced fatal pneumonia was seen despite the presence in the recipient mice of high levels of opsonic serum antibody at titers similar to the protective levels observed after active nasal immunization (33) . We had shown in prior studies that the opsonic antibody in this rabbit antiserum raised against PAO1⌬aroA is directed primarily against the LPS O antigen (31) . Thus, while antibody to the O antigen appears to be the most important immune effector engendered by this live-attenuated vaccine in the setting of pneumonia, surprisingly it is not critical for protection against corneal infection.
One basis for this difference may be the lower doses of P. aeruginosa required in the corneal infection model than in the pneumonia model. Most strains of P. aeruginosa cause significant pathology in mouse eyes at doses of Ͻ10 7 CFU/eye, whereas significant lung infections generally require higher doses for most strains. Furthermore, we have shown that within 15 min of application of P. aeruginosa to the cornea of a scratch-injured mouse eye, 90% of the inoculum is undetectable, likely due to local defenses such as entrapment within the tear film and antimicrobial peptide activity (28) . Thus, effective inocula of P. aeruginosa leading to highly significant corneal pathology likely range from 10 1 to 10 5 CFU/eye, when infecting doses of 10 3 to 10 7 CFU/eye are applied (28) . Also, in the current studies we found that in the eyes of mice examined 48 h after infection and treated with the control antiserum there were about 2 ϫ 10 7 CFU/eye, a lower level of tissue infection than occurs in the lungs of nonimmune mice (31) . Under these circumstances an antibody with less overall effective activity, such as those directed to OMP antigens, could show prophylactic and therapeutic benefits comparable to that of an antibody specific to LPS O antigens, which is effective at protecting against higher challenge doses or higher levels of bacteria that can be found in infected lung tissues.
The lack of essentiality of antibody to the O antigen in the setting of corneal infection is, in one sense, a beneficial situation, since protection against multiple serogroups of P. aeruginosa can potentially be attained with a single vaccine. While other studies of corneal (19) , lung (25) , and burn wound (22, 37) infections have shown significantly diminished potency of non-LPS-based vaccines compared with LPS-based vaccines, we observed protection against challenge doses well above the ID 50 of some strains in the current studies. These findings do not contradict prior results from our group (29) and others (19) showing strong protective efficacy of LPS O antigen-specific antibodies against P. aeruginosa corneal infection. In our prior studies (29) , only LPS-specific immunity was evaluated, primarily using monoclonal antibodies. In serogroup-homologous challenge experiments, these antibodies were quite effective. Broad protection engendered by the PAO1⌬aroA vaccine in the current experiments suggests that when immunization elicits antibodies to a variety of surface antigens, they likely can synergize to diminish pathological consequences from P. aeruginosa corneal infection in a manner analogous to that of antibodies highly specific to LPS O antigens.
Vaccination for experimental corneal infections using whole-cell vaccines has had a somewhat checkered past. Early studies of P. aeruginosa keratitis in rats following immunization with phenol-killed P. aeruginosa suggested that prior immunization might lead to worse disease upon subsequent challenge (43) . In those experiments, the unimmunized rats had bacteria and neutrophils in their corneas but little stromal degradation, while the immunized rats had no bacteria but massive corneal damage. Thus, active immunization strategies might stimulate antibody-mediated or T-cell-orchestrated corneal damage. Indeed, the host's immune response during bacterial keratitis has been shown to play a critical role in the pathogenesis of the disease, perhaps more so than in any other infected tissue. Neutrophils have been found to migrate into the corneal stroma early after the onset of infection (16, 18) . While the neutrophils are required for bacterial killing and removal from the tissue, their presence contributed to corneal damage in some studies (43) . T cells, particularly T helper type 1 (Th1) cells, have also been shown to play a role in the pathogenesis of corneal infections (14) . In the absence of T-cell infiltration into the cornea, neutrophils did not persist and stromal destruction was diminished (15) .
More recently, however, and despite these potential issues, protective efficacy using active immunization was achieved in the studies of Thakur and coworkers (42) , who evaluated various routes of immunization of rats with paraformaldehydekilled P. aeruginosa. They found that, compared with oral and intra-Peyer's patch routes, nasal immunization resulted in the fastest bacterial clearance. In comparison with unimmunized rats, polymorphonuclear leukocyte (PMN) infiltration in the eyes of immunized rats was higher early during the infection, while at later points the number of PMNs diminished in immunized rats but continued to increase in the unimmunized group (42) .
In addition to whole-cell vaccines, a number of studies have evaluated other P. aeruginosa secreted and surface proteins as vaccine candidates for corneal infections. Rabbits immunized with purified protease preparations from P. aeruginosa using active or passive approaches were protected from corneal damage (19) . Active, passive, or topical immunization of mice with purified P. aeruginosa flagella was also found to be beneficial in experimental keratitis (36) . The same group used purified pili as a candidate vaccine and reported that immunization with pili heterologous to the infecting bacterial strain failed to protect against corneal infection despite the fact that heterologous pili were effective at decreasing bacterial binding to the cornea in vitro (35) .
The ability of antibody to antigens in P. aeruginosa OMP preparations to protect against experimental corneal infections has been described by other laboratories. Moon and coworkers found that prophylactic intravenous administration of monoclonal antibodies directed against OMP H2 and/or F (also known as OprF) was protective against corneal damage (23) . Only a single challenge strain was used in those studies, so the broadness of protection was not evaluated. Immunization with recombinant OprF or OprF peptides has been shown to elicit protective immune responses in a number of infection models other than keratitis (11, 30, 40) and has been studied in humans as well (21) . Crystal and coworkers recently reported the use of an adenovirus vector expressing an OprF peptide in the viral capsid as a subcutaneously delivered vaccine against P. aeruginosa pneumonia by using the agar-bead model of murine pneumonia to challenge the immunized mice (45) . The OprF peptide used in those studies stimulated both specific antibody and T-cell responses. We are currently defining the specific antigens recognized by the PAO1⌬aroA antiserum and will determine whether antibodies to OprF, or to this and many other OMPs (which we would expect to see elicited by immunization with a live-attenuated vaccine), are the critical target antigens.
The current study suggests that live-attenuated P. aeruginosa vaccines could be used to prepare passive therapy reagents that might be employed in the treatment of established P. aeruginosa corneal infections. The efficacy of postinfection treatment described here is important, because the clinical utility of prophylactic therapy or active immunization is questionable. As existing antimicrobials become less effective due to microbial resistance, and with few new gram-negative-specific antibiotics in the "pipeline" of the pharmaceutical industry, such new strategies will be important additions to the therapeutic armamentarium against P. aeruginosa corneal infections and will hopefully improve outcomes of this sight-threatening infection.
